What Maze Therapeutics, Inc.'s executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 0 |
| Sells | 30 | 100 |
| Total trades | 40 | 151 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 148,282 | 566,593 |
| Disposed | 211,350 | 759,294 |
| Net activity | −63,068 | −192,701 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Coloma Jason V | Chief Executive Officer | Nov 02 | Open-market sale · S | −5,345 | $31.05 | −$166K | 186,901 |
| Coloma Jason V | Chief Executive Officer | Nov 02 | Open-market sale · S | −26,563 | $30.10 | −$799K | 164,884 |
| Coloma Jason V | Chief Executive Officer | Nov 02 | Open-market sale · S | −336 | $30.91 | −$10.4K | 12,965 |
| Coloma Jason V | Chief Executive Officer | Nov 02 | Open-market sale · S | −2,257 | $30.12 | −$68K | 13,301 |
| Dandekar Atul | CSBO | Oct 29 | Open-market sale · S | −7,500 | $32.07 | −$241K | 32,316 |
| Dandekar Atul | CSBO | Oct 29 | Exercise / conversion · M | +857 | $10.42 | +$8.93K | 39,816 |
| Dandekar Atul | CSBO | Oct 29 | Exercise / conversion · M | +6,643 | $10.42 | +$69.2K | 38,959 |
| Bernstein Harold | President, R&D & CMO | Oct 01 | Open-market sale · S | −16,141 | $26.93 | −$435K | 0 |
| Bernstein Harold | President, R&D & CMO | Oct 01 | Exercise / conversion · M | +16,141 | $10.42 | +$168K | 16,141 |
| Coloma Jason V | Chief Executive Officer | Oct 01 | Open-market sale · S | −31,908 | $27.02 | −$862K | 191,447 |
| Coloma Jason V | Chief Executive Officer | Oct 01 | Open-market sale · S | −2,593 | $27.02 | −$70.1K | 15,558 |
| Dandekar Atul | CSBO | Sep 29 | Open-market sale · S | −7,500 | $27.06 | −$203K | 32,316 |
| Dandekar Atul | CSBO | Sep 29 | Exercise / conversion · M | +7,500 | $10.42 | +$78.2K | 39,816 |
| Bernstein Harold | President, R&D & CMO | Sep 04 | Open-market sale · S | −9,705 | $26.22 | −$255K | 0 |
| Courtney Phillips | GC and Corp. Secretary | Sep 03 | Open-market sale · S | −22 | $25.78 | −$567 | 7,007 |
| Courtney Phillips | GC and Corp. Secretary | Sep 03 | Open-market sale · S | −1,990 | $26.01 | −$51.8K | 7,029 |
| Coloma Jason V | Chief Executive Officer | Sep 03 | Open-market sale · S | −129 | $25.77 | −$3.32K | 27,362 |
| Coloma Jason V | Chief Executive Officer | Sep 03 | Open-market sale · S | −11,282 | $26.01 | −$293K | 27,491 |
| Dandekar Atul | CSBO | Sep 03 | Open-market sale · S | −36 | $25.81 | −$929 | 32,316 |
| Dandekar Atul | CSBO | Sep 03 | Open-market sale · S | −3,207 | $26.01 | −$83.4K | 32,352 |
Loading...